-
Mitsubishi Tanabe Pharma America to Present Real-World Data on ALS Treatment at the 30th International Symposium on ALS/MND
Mitsubishi Tanabe Pharma America, Inc....
Read more
December 4, 2019
-
Mitsubishi Tanabe Pharma America to Spotlight Progress in ALS Research at 30th International Symposium on ALS/MND
Presentations Include U.S. Real-World...
Read more
December 2, 2019
-
Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS
Mitsubishi Tanabe Pharma America, Inc....
Read more
November 25, 2019
-
Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award from the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education
ALS Association Golden West Chapter Honors...
Read more
November 15, 2019
-
First Patient Enrolled in MTPA REFINE-ALS Biomarker Study
Study is Company’s First Clinical...
Read more
October 24, 2019
-
Mitsubishi Tanabe Pharma America Announces Appointment of Gustavo A. Suarez Zambrano, M.D., as Vice President, Medical Affairs
Mitsubishi Tanabe Pharma America, Inc....
Read more
September 26, 2019
-
Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient- Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson’s Disease and Movement Disorders
Investigational Treatment with ND0612...
Read more
September 23, 2019
-
Mitsubishi Tanabe Pharma America to Present on ALS Clinical Programs at 2019 Muscle Study Group Annual Scientific Meeting
Company to Share Details on Collaboration...
Read more
September 20, 2019
-
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated in the United States for Parkinson’s Disease
Mitsubishi Tanabe Pharma America, Inc....
Read more
August 28, 2019
-
More Than 4,000 U.S. Patients with ALS Treated with RADICAVA® (edaravone) in Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports
Mitsubishi Tanabe Pharma America, Inc....
Read more
August 8, 2019
-
Mitsubishi Tanabe Pharma America Presents at 2019 National ALS Registry Annual Meeting in Atlanta
Mitsubishi Tanabe Pharma America, Inc....
Read more
July 23, 2019
-
MTPA Announces Nationwide Database of ALS Infusion Services to Help Patients and Caregivers Identify Local Providers
Launch of Searchable Online Resource...
Read more
May 6, 2019
-
Oxford Biodynamics Joins ALS Biomarker Study Sponsored by Mitsubishi Tanabe Pharma America
Proprietary Technology Platform to Assess...
Read more
May 3, 2019
-
Post-Hoc Analyses of ALS Treatment Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency
Strategic Inclusion Criteria Enabled...
Read more
May 2, 2019
-
Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference
Poster Presentations Include Real-World...
Read more
April 11, 2019
-
Mitsubishi Tanabe Pharma America Announces Names of Teens And Young Adults Chosen for Inclusion In ALSO US™ Initiative
Program Fosters Use of Original Written...
Read more
April 4, 2019
-
Mitsubishi Tanabe Pharma America Announces Collaboration with Massachusetts General Hospital on ALS Biomarker Study
Findings May Help Advance Understanding of...
Read more
March 28, 2019
-
Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy
Mitsubishi Tanabe Pharma America, Inc....
Read more
March 1, 2019
-
Mitsubishi Tanabe Pharma America Accepting Independent Research Program Submissions for RADICAVA® (edaravone) Through March 8
Mitsubishi Tanabe Pharma America, Inc....
Read more
February 21, 2019
-
Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients in the U.S. Have Been Treated With RADICAVA® (edaravone)
Over 1,000 U.S. HCPs Have Prescribed...
Read more
February 6, 2019
-
MTPA Launches National Online Directory of ALS Specialists and Neurologists at Multidisciplinary Centers
Mitsubishi Tanabe Pharma America, Inc....
Read more
January 31, 2019
-
Mitsubishi Tanabe Pharma America Announces Collaborative Study to Identify and Measure Biomarkers in People With ALS
Findings Will Help Further Understanding...
Read more
December 6, 2018
-
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 29th International Symposium on ALS/MND in Glasgow
Presentations Highlight Commitment to...
Read more
November 28, 2018
-
Mitsubishi Tanabe Pharma Group Companies to Present New Data on Investigational Oral Formulation at MNDA
Initial Study Results Show A Single Oral...
Read more
November 15, 2018
-
Mitsubishi Tanabe Pharma America’s ALSO USTM Initiative Begins Accepting Artistic Submissions from Teens Impacted by ALS
Program to Showcase Original, Teen-Created...
Read more
November 5, 2018
-
Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization of ALS Treatment
Mitsubishi Tanabe Pharma Canada, Inc....
Read more
October 4, 2018
-
Mitsubishi Tanabe Pharma America Appoints Joseph Scalia As Vice President of Sales and Marketing
Mitsubishi Tanabe Pharma America, Inc....
Read more
September 24, 2018
-
Mitsubishi Tanabe Pharma America Announces over 3,000 Patients in the U.S. With ALS Have Been Treated With RADICAVA® (Edaravone) in the Last Year
Mitsubishi Tanabe Pharma America, Inc....
Read more
August 8, 2018
-
Mitsubishi Tanabe Pharma America to Present Data on Radicava® (Edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting
Assessments of RADICAVA Clinical Trial...
Read more
June 21, 2018
-
Mitsubishi Tanabe Pharma America Marks One-year Anniversary of Only FDA-approved ALS Treatment Option in the Last 20 Years
Since Becoming Available, More Than 2,500...
Read more
May 7, 2018
-
Mitsubishi Tanabe Pharma America and Neuroderm Announce Parkinson’s Disease Presentations at American Academy of Neurology Annual Meeting
Phase 2 Data on Investigational...
Read more
April 18, 2018
-
Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting
Analysis of Patient U.S. Health Claims...
Read more
April 18, 2018
-
Health Canada Accepts Mitsubishi Tanabe Pharma Corporation’s NDS Filing for Edaravone to Treat ALS, Grants Priority Review
Mitsubishi Tanabe Pharma Canada Launched...
Read more
April 9, 2018
-
Mitsubishi Tanabe Pharma America Initiates Independent Research Program for RADICAVA® (edaravone)
Mitsubishi Tanabe Pharma America, Inc....
Read more
December 20, 2017
-
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston
Mitsubishi Tanabe Pharma America, Inc....
Read more
December 5, 2017
-
Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary
Mitsubishi Tanabe Pharma America, Inc....
Read more
November 30, 2017
-
Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O’Brien as Vice President of Market Access
Mitsubishi Tanabe Pharma America, Inc....
Read more
November 21, 2017
-
Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available
Searchlight SupportTM Staff...
Read more
November 16, 2017
-
Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal
Mitsubishi Tanabe Pharma America, Inc....
Read more
September 7, 2017
-
Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services
Mitsubishi Tanabe Pharma America, Inc....
Read more
September 6, 2017
-
MTPA Perspective Regarding Medicare Coverage
As an FDA-approved therapy, RADICAVATM...
Read more
August 9, 2017
-
First FDA-approved Treatment for ALS in 22 Years Now Available in U.S.
RADICAVATM (edaravone)...
Read more
August 8, 2017
-
MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America
MT Pharma America, Inc. today announced...
Read more
August 1, 2017
-
MT Pharma America Begins Patient Insurance Benefits Investigation Process in Advance of Availability of RADICAVATM (Edaravone)
MT Pharma America, Inc. today announced...
Read more
July 25, 2017
-
Mitsubishi Tanabe Pharma America Enrolls More Than 700 Sites of Care in Newly Created National Infusion Center Directory for ALS Patients
MT Pharma America, Inc. today announced...
Read more
June 30, 2017
-
Mitsubishi Tanabe Pharma America Presents 12-Month RADICAVATM (Edaravone) and Amyotrophic Lateral Sclerosis Data at the European Network for the Cure of ALS (ENCALS) Annual Meeting
MT Pharma America, Inc. (MTPA) today...
Read more
May 18, 2017
-
RADICAVATM (edaravone) Prescribing Information
Read more
May 5, 2017
-
MT Pharma America Announces FDA Approval of RADICAVATM (Edaravone), the First New Treatment Option for ALS in More Than 20 Years
First FDA-approved ALS treatment option in...
Read more
May 5, 2017
-
MT Pharma America to Present Data on Investigational Edaravone and Amyotrophic Lateral Sclerosis at the 2017 American Academy of Neurology Annual Meeting
MT Pharma America, Inc. (MTPA) today...
Read more
April 20, 2017
-
12-month Edaravone Clinical Study Data in ALS Presented at the 27th International Symposium on ALS/MND
Mitsubishi Tanabe Pharma Corporation (Head...
Read more
December 9, 2016
-
The ALS Association Welcomes MT Pharma America as National Corporate Sponsor
The ALS Association is pleased to announce...
Read more
September 20, 2016
-
FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS
Edaravone may be the first ALS treatment...
Read more
August 30, 2016
-
Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States
Mitsubishi Tanabe Pharma Corporation...
Read more
June 20, 2016
-
Mitsubishi Tanabe Pharma Corporation Presents Edaravone Clinical Trial Data in ALS at 2016 American Academy of Neurology Annual Meeting
Mitsubishi Tanabe Pharma Corporation...
Read more
April 20, 2016